Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJakub RadochaPRPaweł RobakSZS. Yousuf Zafar

Discussion

Loading...

Member takes

Overview

Long-term follow-up shows better progression-free survival in patients with relapsed multiple myeloma treated with belantamab mafodotin, suggesting new standards in therapy.

Key Points

  • Median progression-free survival was 32.6 months in patients receiving pomalidomide, dexamethasone, and belantamab mafodotin, compared to 12.5 months with standard therapy.
  • Approximately 43% of patients treated with belantamab mafodotin achieved a complete response or better, indicating substantial treatment benefit.
  • Observational analysis across patients with relapsed multiple myeloma highlighted an increase in minimal residual disease negativity and response duration with belantamab mafodotin.
  • Support is growing for BPd as a potential new standard of care, presenting an effective outpatient option for relapsed multiple myeloma.],

Cite This Study

Radocha et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0bahttps://doi.org/10.1182/blood-2025-2264
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis2025
  2. 2Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis2025
  3. 3Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change2025
  4. 4Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial2025 · 1 citations
  5. 5Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd2025 · 2 citations